Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by gojotv!on Aug 04, 2021 5:05pm
169 Views
Post# 33649905

In Jan 2016 shares were at $0.20. ...By October 2016, $3.96!

In Jan 2016 shares were at $0.20. ...By October 2016, $3.96!The best time to buy SZLS is when the plateau is at its lowest... just like NOW! That's when the share price surges.
Summer doldrums are drawing to a close,
there's a new, wildly qualified, energised CFO,
covid resting revenues are rising with the travel boom,
the Care Oncology merger will be closed within two weeks,
Q2 financials will be released August 16th.
and Aristotle testing as part of the AVRT program will carve itself a huge share of the international oncology market!
Next step - include non-cancer disease diagnostics in Aristotle, such as; alzheimer's, congestive heart disease, and so many more!
In two years, SZLS will not be the same company! In five...wow!
The time is clearly now to get in!
GLTA!


<< Previous
Bullboard Posts
Next >>